Op/Ed: Why Financial Discipline Is the Driver of U.S. Generic Drug Affordability

Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the views or positions of Pharmaceutical Commerce or its associates.

The U.S. generics market does not struggle because prices are too low; it struggles because costs are poorly managed. Although the policy debates are invariably dominated by the aspects of pricing, rebates, and regulatory reforms, another major influential factor of affordability has still been on the back burner, and it is the execution within the pharmaceutical companies. In a segment where business operations are played out in razor-thin margins, a small inefficiency in inventory, logistics, or working capital may mean the difference between a viable product and one that moves out of the market completely.

That is why financial discipline is so much more important in generics than in many other parts of pharma. In an innovative branded business, companies may have enough margin to absorb inefficiency in their operations, which a generic company usually does not. A small cost leakage, be it in the form of expired inventory, expedited freight, or inefficient capital deployment, can erase already limited profit margins. Industry analyses continue to warn that sustained price erosions and weak economics are contributing to exits, underinvestment, and supply fragility.¹

Why Does Inefficiency Hit Generics Companies Harder?

Competitive dynamics in the market for generics in the U.S. create a dynamic of price compression shortly after market entry, and this compresses the margins for manufacturers significantly. While this dynamic creates the benefit of affordability to the healthcare system, it renders product viability more sensitive to underlying cost structure. Industry evidence shows that a significant percentage of approved generics are not commercialized and, even in shortage situations, approved alternatives are often not launched.² This trend indicates another underlying economic limitation in the market in which the viability of supply increasingly depends on cost discipline and not on regulatory approval per se.

In such an environment, inefficiencies are not mere challenges to operations but direct barriers to market participation.

This effect is even more evident with low-cost oral solids and sterile injectables. The FDA has repeatedly observed that shortages are frequently related to manufacturing problems, quality failures, and supply problems.³ In a low-margin environment, these disruptions not only affect the level of service but also weaken the affordability engine of the system by compelling substitutions, emergency sourcing, and higher costs to the providers.

Why Is Inventory Inefficiency a Margins Problem?

Inventory is one of the most critical financial levers in generics because it directly ties up capital while introducing risk.

Industry benchmarking suggests that pharmaceutical companies often operate with 150–180 days of inventory on hand (DIO) due to long and complex supply chains.⁴ While some level of inventory is necessary, excess stock increases:

• Obsolescence and expiry risk
• Storage and handling costs
• Working capital intensity

For a generic manufacturer operating on thin margins, this is both inefficient and economically restrictive.

The financial implications are significant. A company holding $200 million in inventory at 180 days of DIO is effectively carrying six months of stock. Reducing DIO by just 10 days can free approximately $11 million in cash, while a 20-day reduction can free over $22 million (illustrative calculation based on published DIO benchmarks). For generics companies, this capital can fund new launches, dual sourcing, or supply-chain resilience initiatives.

Equally important is inventory quality. Pharmaceutical Commerce has emphasized that effective inventory management is not about minimizing stock, but about balancing availability with waste. In generics, excess inventory that expires or becomes slow-moving represents lost margin that cannot be recovered through pricing.

How Does Freight Inefficiency Impact Low-Margin Portfolios?

Logistics decisions can materially impact cost structures, particularly in generics.

In pharmaceutical supply chains, sea freight can be 50-80% less expensive than air freight, while air freight may cost 4-6 times more depending on route and product characteristics.⁵ When planning failures force last-minute air shipments, the cost differential can significantly erode margins.

For branded products, such costs may be absorbed. For generics, they often cannot.

Poor coordination between demand forecasting, production scheduling, and distribution planning frequently converts low-cost logistics into premium-cost execution. In a compressed pricing environment, this can shift a product from marginally profitable to loss-making.

This is why logistics decisions should not be viewed as operational details, but as core components of financial performance and affordability.

How Can Working-Capital Inefficiency Reduce Resilience?

Working capital is another critical, yet under-appreciated, lever in generics economics.

According to The Hackett Group, US companies collectively hold approximately $1.7 trillion in excess working capital, representing 35% of gross working capital. In the pharmaceutical sector, working capital can represent 25-30% of revenue.⁶

For generics manufacturers, this has direct implications:

• Higher financing costs
• Reduced liquidity
• Limited ability to respond to supply disruptions

Trapped cash is not just a balance-sheet inefficiency; it directly impacts operational flexibility. Companies with inefficient working capital structures are less able to:

• Invest in supply-chain resilience
• Respond to manufacturing disruptions
• Launch new products when market opportunities arise.

Why Does This Matter to US Drug Affordability?

When generic manufacturers absorb inefficiencies, the consequences extend well beyond company financials. The impact of supply instability is ultimately borne by the broader healthcare system, where operational complexity increases significantly during drug shortages. Organizations such as the American Society of Health-System Pharmacists have highlighted that shortages create substantial burdens on hospitals, requiring additional labor, clinical adjustments, and procurement interventions.⁷ These disruptions often force providers to substitute therapies, manually manage constrained inventory, and reallocate already limited resources, reducing overall system efficiency.

As a result, affordability cannot be viewed solely through pricing or policy lenses. It must also be understood through operational discipline, financial execution, and cost management. In a market where pricing flexibility is limited, cost efficiency becomes the primary lever for sustaining both supply and affordability.

How Is Affordability Determined?

For US generic manufacturers, managing inefficiency is about economic survival, not incremental improvement.

In a market where pricing pressure is constant and margins are limited, every avoidable dollar of cost matters. Inventory that expires, shipments that move at premium cost, and capital that remains trapped in inefficient cycles all weaken the sustainability of supply.

The next phase of generic drug affordability will not be driven solely by policy reform. It will be driven by how effectively companies manage their internal economics, through disciplined inventory management, optimized logistics, and efficient capital deployment.

Because ultimately, affordability is not just determined by what companies charge but by how efficiently they operate.

References

1. Association for Accessible Medicines. 2025 U.S. Generic & Biosimilar Medicines Savings Report. Published 2025. Accessed March 30, 2026. https://accessiblemeds.org/resources/reports/2025-savings-report
2. Association for Accessible Medicines. Industry sustainability and pricing pressure insights. Published 2025. Accessed March 30, 2026. https://accessiblemeds.org
3. U.S. Food and Drug Administration. Drug shortages. Published 2026. Accessed March 30, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
4. nVentic. Inventory challenges in pharmaceuticals. Published 2024. Accessed March 30, 2026. https://nventic.com/insights/inventory-challenge-for-pharmaceuticals
5. Kuehne+Nagel. Sea freight vs air freight in healthcare logistics. Published 2023. Accessed March 30, 2026. https://www.kuehne-nagel.com
6. The Hackett Group. 2025 Working Capital Survey. Published 2025. Accessed March 30, 2026. https://www.thehackettgroup.com
7. American Society of Health-System Pharmacists. Drug Shortages Resource Center. Published 2026. Accessed March 30, 2026. https://www.ashp.org/drug-shortages